news
ELRIG UK Drug Discovery 2018 Event
ELRIG’s (European Laboratory Research & Innovation Group) Drug Discovery meeting, will take place at ExCeL, London, UK, located in the heart of the city, from 9 -10 October 2018...
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
whitepaper
Application note: NanoBRETTM assay for monitoring of ligand binding to GPCRs in live cells, using the CLARIOstar® and the PHERAstar® FS
Due to the crucial role of G protein-coupled receptors (GPCRs) in mediating cellular responses to external stimuli, these receptors have been and will remain a prime focus for medical research and the pharmaceutical industry for many years to come. Their importance is especially highlighted by the statistic that 30-50% of…
news
Unique method to find cancer mutations offers chance of improved treatment
Researchers have condensed methods for identifying cancer gene mutations in cells into a single process, to aid understanding of tumours and improve treatment outcomes.
article
Cell-based and biochemical high-throughput screening in 1536 well plates
This webinar shines a spotlight on cell-based and biochemical high-throughput screening in 1536 well plates. Supported by BMG LABTECH, the webinar will take place on 30 October at 4:00pm (GMT).
news
HD vein imaging aids intravenous injections
Near-infrared light can now be used to aid clinicians in identifying veins in patients, especially when this process becomes difficult...
article
How recent advances in flow cytometry can aid drug discovery
For many years, screening assays have been based on high-content imaging systems. However, recent advances in the field of flow cytometry have meant that flow-based assays are now more prevalent. The power of flow cytometry to utilise multiple lasers, multiple fluorochromes and multiplexed assays has meant that assays are not…
news
Transparent high-resolution EEG array allows brain imaging
Researchers have developed a see-through, dual-layered, mesh EEG device which is capable of measuring the electrical activity of individual neurons...
news
Researchers share mass screening method against NSD2 cancer target
Scientists have shared a new method that aims to accelerate the discovery of chemical compounds that inhibit a particular enzyme implicated in several cancers.
article
Next-Generation Sequencing In-Depth Focus 2018
In this In-Depth Focus: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of human genetic diseases, and enabling biomarker discovery at single-cell resolution
article
Using bioactivity profiling to support the progression of phenotypic hits
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.
article
Expert view: Large‑scale stem cell expansion and differentiation
Stem cell-based technologies lay the basis for pioneering approaches in drug screening, toxicology testing, and regenerative medicine. The constant supply of high cell numbers in consistent quality needs scalable culture systems and standardised process conditions.
news
Nuclear PET imaging method developed for tumour detection
Researchers have developed a PET imaging method suitable for many forms of cancer, with high contrast and less inconvenience to patients...
whitepaper
Application Note: Full-length, single-cell RNA-seq with the SMARTer™ ICELL8® Single-Cell System
6 September 2018 | By Takara Bio
The data presented in this application note demonstrates how SMARTer ICELL8 Single-Cell System can be used to generate high-quality RNA-seq libraries that provide full-length transcript sequence information from hundreds of single cells in parallel...
article
Expert view: Managing the complexity of finding new targets and drugging the undruggable
Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.
